Adalimumab in psoriatic arthritis

Carlo Salvarani, Nicolò Pipitone, Mariagrazia Catanoso, Ilaria Chiarolanza, Luigi Boiardi, Andrea Caruso, Giulia Pazzola, Pierluigi Macchioni, Vito Di Lernia, Giuseppe Albertini

Research output: Contribution to journalArticlepeer-review


Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease, enthesitis, and dactylitis. ADA significantly inhibited structural changes on radiographs, lessened disability, and improved quality of life in patients with active PsA. One study showed the efficacy of 24-week ADA therapy on bone marrow edema and erosions, as measured by magnetic resonance imaging. The clinical and radiographic efficacy of ADA demonstrated during short-term treatment was sustained during longterm treatment. ADA was generally well tolerated and its safety profile was similar to that reported in studies of ADA in rheumatoid arthritis. Overall, ADA has a favorable risk-benefit profile in PsA. The combination of ADA and cyclosporine seems to be more effective than ADA monotherapy in patients with active PsA and inadequate response to methotrexate; however, this observation must be confirmed in RCT. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)77-81
Number of pages5
JournalJournal of Rheumatology
Issue numberSUPPL. 89
Publication statusPublished - Jul 2012


  • Adalimumab
  • Psoriasis
  • Psoriatic arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)


Dive into the research topics of 'Adalimumab in psoriatic arthritis'. Together they form a unique fingerprint.

Cite this